Toll L
Department of Neuroscience, SRI International, Menlo Park, California, USA.
J Pharmacol Exp Ther. 1995 May;273(2):721-7.
Binding studies were conducted with intact SH-SY5Y cells, using the mu-opioid-selective antagonist [3H]D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2. Previous studies had demonstrated equilibrium binding constants generally higher than those found when binding to membrane preparations for most opioid agonists. Studies on various other G protein-coupled receptors had shown that receptor internalization led to low apparent affinities for agonists and that short or low-temperature incubations could reveal high-affinity binding components. In SH-SY5Y cells, short (1-min) and 4 degrees C incubations did not reveal high-affinity binding components. Nonequilibrium binding experiments could also be used to compare binding affinities of opiate agonists with activity at mu receptors in the cells. SH-SY5Y cells have functional mu and delta receptors. mu Receptors can be measured independently of delta receptors if activity is determined in the presence of the delta antagonist ICI 174,864. When both binding and activity, as measured by inhibition of forskolin-stimulated cAMP accumulation, were conducted for 10 min, the ratio of binding IC50 to activity IC50 could give an indication of the relative efficacy of opioid agonists. These studies indicated that morphine has slightly lower efficacy than etorphine and the peptides DAMGO and DADLE. Each of these compounds has significantly higher efficacy than ethylketocyclazocine and the partial agonist buprenorphine.
使用μ阿片样物质选择性拮抗剂[3H]D-苯丙氨酸-半胱氨酸-酪氨酸-D-色氨酸-鸟氨酸-苏氨酸-青霉胺-苏氨酸-NH2对完整的SH-SY5Y细胞进行结合研究。先前的研究表明,对于大多数阿片样物质激动剂,其平衡结合常数通常高于与膜制剂结合时的常数。对各种其他G蛋白偶联受体的研究表明,受体内化导致激动剂的表观亲和力较低,并且短时间或低温孵育可能会揭示高亲和力结合成分。在SH-SY5Y细胞中,短时间(1分钟)和4℃孵育并未揭示高亲和力结合成分。非平衡结合实验也可用于比较阿片样物质激动剂的结合亲和力与细胞中μ受体的活性。SH-SY5Y细胞具有功能性的μ和δ受体。如果在δ拮抗剂ICI 174,864存在下测定活性,则可以独立于δ受体测量μ受体。当通过抑制福斯高林刺激的cAMP积累来测量结合和活性时,进行10分钟,结合IC50与活性IC50的比率可以表明阿片样物质激动剂的相对效力。这些研究表明,吗啡的效力略低于埃托啡以及肽DAMGO和DADLE。这些化合物中的每一种的效力都明显高于乙基酮环唑新和部分激动剂丁丙诺啡。